Historically, biotech startups have tried to bring in new money every eighteen months or so — ideally raising enough to keep them going for the next few years. But in the last year, that timeline has become noticeably compressed.
Several companies have crammed multiple venture financings into a single year this year, and some have even managed to go public less than eighteen months after launch.
About the Author Reprints
